Fsp 1

Immunohistochemical staining was performed according to a previously established protocol28 (link). Primary antibodies against ACTA2 (Sigma-Aldrich, St. Louis, MO, USA), VIM (Santa Cruz Biotechnology, California, USA), FSP-1 (Thermo Scientific, Fremont, CA, USA), PCNA (Dako, Glostrup, Denmark), activated β-catenin (Sigma-Aldrich), and TAZ (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were used. TUNEL staining was performed using a commercial kit (Millipore, Billerica, MA, USA), in accordance with the manufacturer’s instructions.

The antibodies used in this study were as follows: Atg7 (Sigma-Aldrich, St. Louis, MO, USA), LC3B (anti-LC3B; Sigma-Aldrich, St. Louis, MO, USA), P62 (PROGEN Biotechnik GmbH, Heidelberg, Germany), fibronectin (DAKO, Glostrupp, Denmark), TGF-β (R&D systems, Minneapolis, Minnesota, USA), E-cadherin (BD Transduction Laboratories, Lexington, KY, USA), α-SMA (Sigma-Aldrich, St. Louis, MO, USA), vimentin (Santa Cruz Biotechnoligy, California, USA), PAI-1 (Santa Cruz Biotechnoligy, California, USA), NLRP3 (Adipogen, San Diego, USA), aspase-1 (Santa Cruz Biotechnoligy), FSP1 (Thermo scientific, Fremont, USA), IL-β (Cell signaling technology, Inc. Danvers, MA, USA), NF-KB (Abcam, Cambridge, UK), 8-OHdG (JaICA, haruoka, Fukuroi, Shiizuoka, Japan) and GAPDH (Santa Cruz Biotechnology) were used. Apoptosis was detected using an ApopTag Peroxidase In Situ Apoptosis Detection Kit (Millipore, Billerica, MA, USA).